419,900 Shares in Cryoport, Inc. (NASDAQ:CYRX) Purchased by Point72 Asset Management L.P.

Point72 Asset Management L.P. acquired a new stake in Cryoport, Inc. (NASDAQ:CYRX) during the third quarter, according to its most recent 13F filing with the SEC. The fund acquired 419,900 shares of the company’s stock, valued at approximately $3,405,000. Point72 Asset Management L.P. owned 0.85% of Cryoport as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CYRX. Thematics Asset Management raised its position in shares of Cryoport by 176.2% in the third quarter. Thematics Asset Management now owns 1,705,000 shares of the company’s stock valued at $13,828,000 after purchasing an additional 1,087,800 shares during the period. Fred Alger Management LLC raised its holdings in Cryoport by 49.9% during the 3rd quarter. Fred Alger Management LLC now owns 2,698,768 shares of the company’s stock valued at $21,887,000 after acquiring an additional 898,481 shares during the period. AXA S.A. lifted its position in shares of Cryoport by 274.2% during the second quarter. AXA S.A. now owns 873,217 shares of the company’s stock worth $6,034,000 after acquiring an additional 639,855 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Cryoport by 52.9% in the second quarter. Assenagon Asset Management S.A. now owns 1,477,693 shares of the company’s stock worth $10,211,000 after acquiring an additional 511,064 shares during the period. Finally, Algert Global LLC grew its position in shares of Cryoport by 282.7% in the third quarter. Algert Global LLC now owns 247,483 shares of the company’s stock valued at $2,007,000 after purchasing an additional 182,808 shares in the last quarter. Institutional investors own 92.90% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on CYRX. UBS Group raised their target price on Cryoport from $7.00 to $9.00 and gave the stock a “neutral” rating in a research note on Friday, October 18th. Roth Mkm cut their price objective on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, November 8th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $12.50.

Insider Transactions at Cryoport

In other Cryoport news, Director Ramkumar Mandalam sold 7,369 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $7.46, for a total transaction of $54,972.74. Following the sale, the director now owns 59,497 shares in the company, valued at $443,847.62. This trade represents a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Jerrell Shelton sold 50,000 shares of the company’s stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $6.51, for a total value of $325,500.00. Following the completion of the transaction, the chief executive officer now owns 731,897 shares of the company’s stock, valued at $4,764,649.47. The trade was a 6.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 109,869 shares of company stock valued at $735,673. 10.10% of the stock is owned by corporate insiders.

Cryoport Price Performance

Shares of NASDAQ CYRX opened at $7.33 on Monday. The stock’s 50-day simple moving average is $7.31 and its two-hundred day simple moving average is $8.18. Cryoport, Inc. has a twelve month low of $5.32 and a twelve month high of $20.10. The firm has a market capitalization of $362.33 million, a P/E ratio of -2.17 and a beta of 1.62. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.